ArticleScientific reports2026
Dynamic optical coherence microscope integrated with cell-cultivation chamber enabled longitudinal and early-stage assessment of tumor spheroid-drug interaction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We present an integrated system that combines dynamic optical coherence tomography (DOCT) with a small cell-cultivation chamber to enable high-sensitivity and high-temporal-resolution imaging of tumor spheroid's drug response. Unlike conventional OCT-based volume measurement, which only captures late-stage morphological changes, our system captures early-stage changes in spheroid's intracellular activity. The compact chamber, positioned beneath the DOCT probe, maintains a cell-culture environment (37 [Formula: see text]C, 5% CO[Formula: see text]) while allowing frequent system access without disturbing the cultivation environment. The proposed system was used to monitor human breast cancer (MCF-7) spheroids response to doxorubicin hydrochloride, tamoxifen citrate, and paclitaxel over 100 hours at 4-hour intervals. While standard OCT-based volume measurement failed to detect early-stage drug concentration impacts, DOCT signals revealed statistically significant differences among the drug concentrations as early as 12 hours. Additionally, high-temporal-resolution imaging at 30-minute intervals over 100 hours revealed rapid and subtle changes in the spheroid morphology and DOCT signals. The results demonstrate that the proposed integrated system of DOCT and cultivation chamber provides a superior, early-readout platform for label-free anti-cancer drug testing compared to traditional structural OCT imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.